.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Predict branded drug patent expiration
  • Obtain formulation and manufacturing information

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Deloitte
Johnson and Johnson
Daiichi Sankyo
Fuji
Farmers Insurance
Mallinckrodt
Medtronic
Baxter
Fish and Richardson
Merck

Generated: July 22, 2017

DrugPatentWatch Database Preview

Atazanavir sulfate; cobicistat - Generic Drug Details

« Back to Dashboard

What are the generic drug sources for atazanavir sulfate; cobicistat and what is the scope of atazanavir sulfate; cobicistat freedom to operate?

Atazanavir sulfate; cobicistat
is the generic ingredient in one branded drug marketed by Bristol-myers Squibb and is included in one NDA. There are four patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Atazanavir sulfate; cobicistat has two hundred and sixteen patent family members in forty-eight countries.

There are twenty-three drug master file entries for atazanavir sulfate; cobicistat. One supplier is listed for this compound.

Summary for Generic Name: atazanavir sulfate; cobicistat

Tradenames:1
Patents:4
Applicants:1
NDAs:1
Drug Master File Entries: see list23
Suppliers / Packagers: see list1
Clinical Trials: see list875
Drug Prices:see low prices
DailyMed Link:atazanavir sulfate; cobicistat at DailyMed
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Bristol-myers Squibb
EVOTAZ
atazanavir sulfate; cobicistat
TABLET;ORAL206353-001Jan 29, 2015RXYesYes5,849,911*PED► SubscribeY► Subscribe
Bristol-myers Squibb
EVOTAZ
atazanavir sulfate; cobicistat
TABLET;ORAL206353-001Jan 29, 2015RXYesYes6,087,383*PED► SubscribeY► Subscribe
Bristol-myers Squibb
EVOTAZ
atazanavir sulfate; cobicistat
TABLET;ORAL206353-001Jan 29, 2015RXYesYes► Subscribe► Subscribe
Bristol-myers Squibb
EVOTAZ
atazanavir sulfate; cobicistat
TABLET;ORAL206353-001Jan 29, 2015RXYesYes8,148,374► SubscribeYY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Generic Ingredient: atazanavir sulfate; cobicistat

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,486,942Modulators of pharmacokinetic properties of therapeutics► Subscribe
9,139,541Modulators of pharmacokinetic properties of therapeutics► Subscribe
7,939,553Modulators of pharmacokinetic properties of therapeutics► Subscribe
6,110,946 Antivirally active heterocyclic azahexane derivatives► Subscribe
8,088,770Modulators of pharmacokinetic properties of therapeutics► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: atazanavir sulfate; cobicistat

Country Document Number Estimated Expiration
Denmark2487163► Subscribe
Austria219057► Subscribe
CroatiaP20150744► Subscribe
Slovenia2487161► Subscribe
New Zealand509046► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: ATAZANAVIR SULFATE; COBICISTAT

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2015 00060Denmark► SubscribePRODUCT NAME: COBICISTAT ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF; REG. NO/DATE: EU/1/13/830/001-002 20130527
/2015Austria► SubscribePRODUCT NAME: COBICISTAT ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON; REGISTRATION NO/DATE: EU/1/13/830 (MITTEILUNG) 20130527
0203Netherlands► Subscribe300203, 20170414, EXPIRES: 20190301
189Luxembourg► Subscribe91189, EXPIRES: 20190302
2016038Lithuania► SubscribePRODUCT NAME: ELVITEGRAVIRAS + KOBICISTATAS + EMTRICITABINAS + TENOFOVIRALAFENAMIDAS; REGISTRATION NO/DATE: EU/1/15/1061 20151119
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Novartis
McKesson
Medtronic
Covington
Federal Trade Commission
Citi
Moodys
US Army
Cantor Fitzgerald
US Department of Justice

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot